

```
? b 411
 02may06 06:46:35 User208650 Session D824.2
    $0.00    0.102 DialUnits File410
$0.00  Estimated cost File410
$0.00  Estimated cost this search
$0.41  Estimated total session cost  0.220 DialUnits
File 411:DIALINDEX(R)
```

```
DIALINDEX(R)
  (c) 2006 Dialog
```

```
*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
? sf medicine
>>>      135 is unauthorized
>>>      138 is unauthorized
>>>      162 is unauthorized
>>>3 of the specified files are not available
  You have 23 files in your file list.
  (To see banners, use SHOW FILES command)
? s rhinitis and ?loratadin?
```

```
Your SELECT statement is:
  s rhinitis and ?loratadin?
```

Items	File
-----	-----

```
No files have one or more items; file list includes 23 files.
One or more terms were invalid in 22 files.
```

```
? s rhinitis and loratadin?
```

```
Your SELECT statement is:
  s rhinitis and loratadin?
```

Items	File
-----	-----

250	5: Biosis Previews(R)_1969-2006/Apr W4
482	34: SciSearch(R) Cited Ref Sci_1990-2006/Apr W4
2	65: Inside Conferences_1993-2006/Apr 28
75	71: ELSEVIER BIOBASE_1994-2006/Apr W5
926	73: EMBASE_1974-2006/May 02
1	91: MANTIS(TM)_1880-2006/Feb
12	94: JICST-EPlus_1985-2006/Feb W1
13	98: General Sci Abs_1984-2004/Dec
154	144: Pascal_1973-2006/Apr W2
133	149: TGG Health&Wellness DB(SM)_1976-2006/Apr W3
341	155: MEDLINE(R)_1951-2006/May 03
111	156: ToxFile_1965-2006/Apr W3
6	159: Cancerlit_1975-2002/Oct
1	164: Allied & Complementary Medicine_1984-2006/Apr
1	172: EMBASE Alert_2006/May 02
69	399: CA SEARCH(R)_1967-2006/UD=14418
24	434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
8	444: New England Journal of Med._1985-2006/Apr W3

```
18 files have one or more items; file list includes 23 files.
```

```
? rf
```

```
Your last SELECT statement was:
  S RHINITIS AND LORATADIN?
```

Ref	Items	File
N1	926	73: EMBASE_1974-2006/May 02
N2	482	34: SciSearch(R) Cited Ref Sci_1990-2006/Apr W4
N3	341	155: MEDLINE(R)_1951-2006/May 03
N4	250	5: Biosis Previews(R)_1969-2006/Apr W4
N5	154	144: Pascal_1973-2006/Apr W2
N6	133	149: TGG Health&Wellness DB(SM)_1976-2006/Apr W3
N7	111	156: ToxFile_1965-2006/Apr W3
N8	75	71: ELSEVIER BIOBASE_1994-2006/Apr W5
N9	69	399: CA SEARCH(R)_1967-2006/UD=14418
N10	24	434: SciSearch(R) Cited Ref Sci_1974-1989/Dec

18 files have one or more items; file list includes 23 files.

- Enter P or PAGE for more -

? b n1-n10
02may06 06:49:09 User208650 Session D824.3
\$3.17 1.197 DialUnits File411
\$3.17 Estimated cost File411
\$0.80 TELNET
\$3.97 Estimated cost this search
\$4.38 Estimated total session cost 1.416 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 73:EMBASE 1974-2006/May 02
(c) 2006 Elsevier Science B.V.
File 34:SciSearch(R) Cited Ref Sci 1990-2006/Apr W4
(c) 2006 Inst for Sci Info
File 155: MEDLINE(R) 1951-2006/May 03
(c) format only 2006 Dialog
File 5:Biosis Previews(R) 1969-2006/Apr W4
(c) 2006 BIOSIS
File 144:Pascal 1973-2006/Apr W2
(c) 2006 INIST/CNRS
File 149:TGG Health&Wellness DB(SM) 1976-2006/Apr W3
(c) 2006 The Gale Group
File 156:ToxFile 1965-2006/Apr W3
(c) format only 2006 Dialog
*File 156: ToxFile has resumed updating with UD20051205.
File 71:ELSEVIER BIOBASE 1994-2006/Apr W5
(c) 2006 Elsevier Science B.V.
File 399:CA SEARCH(R) 1967-2006/UD=14418
(c) 2006 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info

Set	Items	Description
? s rhinitis and loratadin?	89917	RHINITIS
	7049	LORATADIN?
S1	2565	RHINITIS AND LORATADIN?
?`rd		
Processing	-	Examined 1200 records
Processing	-	Examined 2400 records
S2	1570	RD (unique items)
? s s2 and (descarb?(5n)loratadin?)	1570	S2
	4249	DESCARB?
	7049	LORATADIN?
	178	DESCARB? (5N)LORATADIN?
S3	10	S2 AND (DESCARB? (5N)LORATADIN?)

? t/5/1-10

3/5/1 (Item 1 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier Science B.V. All rts. reserv.

07104486 EMBASE No: 1997368522

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Kosoglou T.; Radwanski E.; Batra V.K.; Lint J.M.; Christopher D.; Affrime M.B.

T. Kosoglou, Clinical Pharmacology Department, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033 United States Clinical Therapeutics (CLIN. THER.) (United States) 1997, 19/5 (1002-1012)

CODEN: CLTHD ISSN: 0149-2918

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 15

The pharmacokinetic profiles of single and multiple doses of **loratadine**, **descarboethoxyloratadine** (DCL) (the major active metabolite of **loratadine**), and pseudoephedrine were determined in a randomized, open-label, two-way crossover study in 24 healthy men. Subjects received a single dose (day 1) and multiple doses (days 3 to 10) of a once-daily (QD) formulation of **loratadine** 10 mg in an immediate-release coating and pseudoephedrine sulfate 240 mg in an extended-release corn (CLAR-TIN-D(R) 24 HOUR tablets), and a twice-daily (BID) formulation of **loratadine** 5 mg in an immediate-release coating and pseudoephedrine sulfate 120 mg, with 60 mg in an immediate-release coating and 60 mg in the barrier-protected core (CLARITIN-DDelta 12 HOUR tablets) in study sessions, each separated by a 10-day washout period. Both regimens were safe and well tolerated. On day 1, plasma ***loratadine***, DCL, and pseudoephedrine concentrations were higher following the QD formulation than following the BID formulation, as expected. On day 10, **loratadine** and DCL maximum plasma concentration (C(max)) values were, on average, 87% and 35% higher, respectively, for the QD formulation than for the BID formulation; however, the values of the area under the plasma concentration-time curve from 0 to 24 hours (AUC_{inf} 0_{inf} -_{inf} 2_{inf} 4) for **loratadine** and DCL were equivalent (90% confidence interval (CI): 83% to 110% for ***loratadine***; 90% to 107% for DCL). On day 10, pseudoephedrine C(max) and AUC_{inf} 0_{inf} -_{inf} 2_{inf} 4 values were equivalent (90% CI for C(max): 94% to 109%; for AUC: 91% to 106%) for the two formulations, and lower pseudoephedrine concentrations were observed from 16 to 24 hours with the QD formulation. Both ***loratadine***/pseudoephedrine formulations produced equivalent **loratadine** and DCL AUC_{inf} 0_{inf} -_{inf} 2_{inf} 4 values and equivalent pseudoephedrine C(max) and AUC_{inf} 0_{inf} -_{inf} 2_{inf} 4 values following multiple dosing. The lower pseudoephedrine concentrations in the evening with the QD formulation may minimize the potential for insomnia in patients when compared with the BID formulation.

MANUFACTURER NAMES: schering plough/USA

DRUG DESCRIPTORS:

***loratadine**--adverse drug reaction--ae; ***loratadine**--clinical trial--ct; ***loratadine**--drug therapy--dt; ***loratadine**--pharmaceutics--pr; ***loratadine**--pharmacokinetics--pk; ***pseudoephedrine**--adverse drug reaction--ae; ***pseudoephedrine**--clinical trial--ct; ***pseudoephedrine**--drug therapy--dt; ***pseudoephedrine**--pharmaceutics--pr; ***pseudoephedrine**--pharmacokinetics--pk; *claritin d--adverse drug reaction--ae; *claritin d--clinical trial--ct; *claritin d--drug therapy--dt; *claritin d--pharmaceutics--pr; *claritin d--pharmacokinetics--pk

MEDICAL DESCRIPTORS:

*allergic rhinitis--drug therapy--dt
drug formulation; drug blood level; insomnia--side effect--si; drug safety;
drug tolerance; headache--side effect--si; human; male; normal human;
clinical trial; randomized controlled trial; crossover procedure;
controlled study; adult; article
CAS REGISTRY NO.: 79794-75-5 (***loratadine***); 345-78-8, 7460-12-0,
90-82-4 (pseudoephedrine)

SECTION HEADINGS:

011 Otorhinolaryngology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reaction Titles
039 Pharmacy

3/5/2 (Item 2 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier Science B.V. All rts. reserv.

06326040 EMBASE No: 1995348533

Antiallergic properties of loratadine: A review
Bousquet J.; Czarlewski W.; Danzig M.R.
Cliniques des Maladies Respiratoire, Centre Hospitalier Universitaire,
Hopital Arraud de Villeneuve, 34295 Montpellier-Cedex France
Advances in Therapy (ADV. THER.) (United States) 1995, 12/5 (283)
CODEN: ADTHE ISSN: 0741-238X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Histamine is a major mediator of the allergic reaction, and histamine H₁-receptor antagonists have a long history of clinical efficacy in a variety of allergic disorders. ***Loratadine*** is one of a new generation of antihistamines that lack central nervous system depressant or anticholinergic effects and do not cause torsades de pointes-type arrhythmias. ***Loratadine*** and other second-generation antihistamines also possess additional antiallergic properties beyond those affected through histamine H₁-receptors. ***Loratadine*** and its active metabolite, **descarboxyethoxyloratadine**, help to stabilize mast cells, as evidenced by their ability to inhibit the release of histamine, leukotrienes, and prostaglandins induced by both IgE-dependent and -independent stimuli in animal and human *in vitro* studies. ***Loratadine*** also inhibits stimulus-induced bronchospasm, airway resistance, nasal mucous production, and nasal permeability in some animal models. In patients with seasonal allergy, loratadine markedly reduces symptoms induced by allergen exposure. Analysis of secretory fluids and tissues after challenge indicates that loratadine interferes with mediator release. Recruitment of inflammatory cells to the site of the allergic insult is also disturbed by loratadine, suggesting that the drug may inhibit upregulation of molecules involved in cell adhesion and migration and perhaps may interfere with the cytokine cascade through its ability to stabilize mast cells and limit incursion of inflammatory cells.

DRUG DESCRIPTORS:

*allergen; *antiallergic agent--clinical trial--ct; *antiallergic agent--drug dose--do; *antiallergic agent--drug therapy--dt; *antiallergic agent--pharmacology--pd; *histamine--endogenous compound--ec; *histamine H₁ receptor antagonist--pharmacology--pd; *histamine H₁ receptor antagonist--drug therapy--dt; *histamine H₁ receptor antagonist--drug dose--do; *histamine H₁ receptor antagonist--clinical trial--ct; *leukotriene--endogenous compound--ec; *loratadine--pharmacology--pd; *loratadine--clinical trial--ct; *loratadine--drug therapy--dt; *loratadine--drug dose--do; *loratadine--drug comparison--cm; astemizole--clinical trial--ct; astemizole--drug comparison--cm; astemizole

--drug therapy--dt; calcium--endogenous compound--ec; cell adhesion molecule--endogenous compound--ec; drug metabolite; histamine release inhibitor--pharmacology--pd; histamine release inhibitor--drug therapy--dt; histamine release inhibitor--drug dose--do; histamine release inhibitor--clinical trial--ct; immunoglobulin e--endogenous compound--ec; placebo; prostaglandin--endogenous compound--ec; terfenadine--pharmacology--pd; terfenadine--drug therapy--dt; terfenadine--drug comparison--cm; terfenadine--clinical trial--ct

MEDICAL DESCRIPTORS:

*allergic rhinitis--drug therapy--dt; *allergy--drug therapy--dt; *bronchospasm; *histamine release; *rhinoconjunctivitis--drug therapy--dt airway resistance; article; blood vessel permeability; clinical trial; dose response; drug mechanism; human; inflammatory cell; mediator; nonhuman; nose mucus; provocation test; skin test
CAS REGISTRY NO.: 51-45-6, 56-92-8, 93443-21-1 (histamine); 79794-75-5 (loratadine); 68844-77-9 (astemizole); 7440-70-2 (calcium); 37341-29-0 (immunoglobulin e); 50679-08-8 (terfenadine)

SECTION HEADINGS:

- 013 Dermatology and Venereology
- 015 Chest Diseases, Thoracic Surgery and Tuberculosis
- 026 Immunology, Serology and Transplantation
- 030 Clinical and Experimental Pharmacology
- 037 Drug Literature Index

3/5/3 (Item 3 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

06121120 EMBASE No: 1995151857

Inhibitory activity of-loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells

Vignola A.M.; Crampette L.; Mondain M.; Sauvere G.; Czarlewski W.; Bousquet J.; Campbell A.M.

Clinique Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, 34295 Montpellier Cedex 5 France

Allergy: European Journal of Allergy and Clinical Immunology (ALLERGY EUR. J. ALLERGY CLIN. IMMUNOL.) (Denmark) 1995, 50/3 (200-203)

CODEN: LLRGD ISSN: 0105-4538

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Nasal epithelial cells represent the first barrier against noxious agents and allergens. In allergic ***rhinitis***, these cells are activated and histamine may be involved in this activation. ***Loratadine*** and one of its active metabolites, descarboethoxyloratadine, were studied for their ability to reduce the activation of nasal epithelial cells by histamine. Nasal turbinates or polyps were removed during surgery from 19 subjects, and nasal epithelial cells were recovered after enzymatic digestion. The in vitro activation of epithelial cells with histamine using an optimal dose (1 μ M) and an optimal time (24 h) of incubation was studied, and the effect of loratadine or descarboethoxyloratadine (10 μ M) was investigated. The expression of membrane markers (intercellular adhesion molecule-1 (ICAM-1) and a human leukocyte class II antigen (HLA-DR) was assessed by immunocytochemical analysis using an alkaline-antialkaline phosphatase (APAAP) system. The spontaneous expression of both markers was not significantly different in cells recovered from nasal turbinates or polyps, and there was a highly significant increase in the numbers of cells expressing ICAM-1 and HLA-DR following incubation with histamine.

Loratadine or descarboethoxyloratadine significantly blocked these effects. This study shows a new possible antiallergic effect of Hinf 1-blockers and suggests that their effects on epithelial cells may be relevant in vivo.

DRUG DESCRIPTORS:

*HLA DR antigen--endogenous compound--ec; *antiallergic agent; *histamine--endogenous compound--ec; *histamine--pharmacology--pd; *intercellular adhesion molecule 1--endogenous compound--ec; *loratadine--pharmacology--pd; *loratadine--clinical trial--ct histamine h1 receptor antagonist; unclassified drug

MEDICAL DESCRIPTORS:

*nose mucosa adult; article; biopsy; clinical article; clinical trial; human; human cell; human tissue; priority journal

DRUG TERMS (UNCONTROLLED): descarboethoxyloratadine--pharmacology--pd; descarboethoxyloratadine--clinical trial--ct

CAS REGISTRY NO.: 51-45-6, 56-92-8, 93443-21-1 (histamine); 126547-89-5 (intercellular adhesion molecule 1); 79794-75-5 (loratadine)

SECTION HEADINGS:

011 Otorhinolaryngology

026 Immunology, Serology and Transplantation

030 Clinical and Experimental Pharmacology

037 Drug Literature Index

3/5/4 (Item 4 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

03969544 EMBASE No: 1989138540

Loratadine: A nonsedating antihistamine with once-daily dosing

Barenholtz H.A.; McLeod D.C.

Department of Pharmacy, University of Michigan, Ann Arbor, MI United States

DICP, Annals of Pharmacotherapy (DICP ANN. PHARMACOTHER.) (United States) 1989, 23/6 (445-450)

CODEN: DAPHE ISSN: 1042-9611

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH SUMMARY LANGUAGE: FRENCH; ENGLISH

Loratadine is an addition to the class of nonsedating antihistamines which includes terfenadine, astemizole, and acrivastine.

Loratadine is chemically related to the tricyclic antidepressants. Animal data have shown that insignificant amounts of **loratadine** enter the brain, and it has a threefold greater affinity for peripheral as compared with central histamineinf 1-receptors. ***Loratadine*** has one main metabolite, **descarbethoxyloratadine**, which is four times more active than the parent drug. ***Loratadine*** reaches peak plasma concentration in 1-2 hours; the metabolite does so in 3-4 hours. Their respective elimination half-lives are about 10 and 20 hours. Onset of action is within 1 hour and duration is at least 24 hours. Once-daily dosing is recommended. Generally ***loratadine*** is as efficacious as existing antihistamines in relieving symptoms of allergic rhinitis, urticaria, and in suppressing wheal formation. Reports of sedation and other adverse reactions are no more frequent than found with placebo. Tachyphylaxis has not been noted in humans, and there is minimal potential for drug interactions based on animal data. ***Loratadine*** and terfenadine have comparable therapeutic applications. Both have shown minimal adverse effects, but **loratadine** has a quicker onset and longer duration of action. These two agents are useful for acute allergic reactions. In contrast, astemizole has an onset of action of several days and is most useful for prophylactic treatment of seasonal allergies.

BRAND NAME/MANUFACTURER NAME: sch 434/schering

MANUFACTURER NAMES: burroughs wellcome; janssen; merrell dow pharmaceuticals; schering

DRUG DESCRIPTORS:

*histamine receptor; *loratadine--adverse drug reaction--ae; *
loratadine--pharmacology--pd; *loratadine--drug therapy--dt; *
loratadine--clinical trial--ct
acrivastine; astemizole; pseudoephedrine; claritin d; terfenadine
MEDICAL DESCRIPTORS:
*allergic rhinitis--drug therapy--dt; *chronic urticaria--drug
therapy--dt; *pharmacokinetics
drug absorption; drug distribution; drug elimination; drug metabolism;
sedation; short survey; human; priority journal
CAS REGISTRY NO.: 79794-75-5 (***loratadine***); 87848-99-5 (acrivastine);
68844-77-9 (astemizole); 345-78-8, 7460-12-0, 90-82-4 (pseudoephedrine)
; 50679-08-8 (terfenadine)

SECTION HEADINGS:

011 Otorhinolaryngology
013 Dermatology and Venereology
026 Immunology, Serology and Transplantation
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reaction Titles

3/5/5 (Item 1 from file: 34)
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

13382859 Genuine Article#: 876YW Number of References: 27
Title: Inhibition of nasal polyp mast cell and eosinophil activation by
desloratadine
Author(s): Kowalski ML (REPRINT) ; Lewandowska A; Wozniak J; Makowska J;
Jankowski A; DuBuske L
Corporate Source: Med Univ Lodz,Dept Clin Immunol & Allergy, Fac Med, 251
Pomorska Str/PL-92213 Lodz//Poland/ (REPRINT); Med Univ Lodz,Dept Clin
Immunol & Allergy, Fac Med,PL-92213 Lodz//Poland/; Med Univ Lodz,ENT
Dept,Lodz//Poland/; Immunol Res Inst New England,Fitchburg//MA/
Journal: ALLERGY, 2005, V60, N1 (JAN), P80-85
ISSN: 0105-4538 Publication date: 20050100
Publisher: BLACKWELL MUNKSGAARD, 35 NORRE SOGADE, PO BOX 2148, DK-1016
COPENHAGEN, DENMARK
Language: English Document Type: ARTICLE
Geographic Location: Poland; USA
Journal Subject Category: ALLERGY; IMMUNOLOGY
Abstract: Nasal polyp tissue which contains mast cells and eosinophils is
similar to the inflamed airway mucosa in cellular composition and
mediator content. This investigation assessed the effect of
desloratadine (DL), on activation of cells in nasal polyp tissue.
Polyps were obtained from 22 patients with chronic rhinosinusitis [nine
aspirin acetylosalitic acid (ASA)-sensitive and 13 ASA-tolerant]. Polyp
tissue was dispersed by digestion, and preincubated with DL and
incubated with anti-immunoglobulin E (IgE) or calcium ionophore. LTC4,
eosinophil cationic protein (ECP) and tryptase concentrations in
supernatants were measured by immunoassays. Desloratadine (1, 10 and 50
muM) inhibited calcium ionophore-induced LTC4 release by a mean of 29%,
50% and 63% respectively, and anti-IgE-induced LTC4 release by a mean
of 27%, 35% and 39% respectively. Calcium ionophore-induced tryptase
release was inhibited 60% and 69% by 10 and 50 muM of DL, respectively,
and anti-IgE-induced tryptase release was inhibited 33%, 47% and 66%
for 1, 10 and 50 muM of DL. Desloratadine 10 muM and 50 muM inhibited
ECP release by 45% and 48% respectively. Polyp tissue from
ASA-sensitive patients when compared with ASA-tolerant patients
released at baseline significantly more ECP (medians 120.0 mug/ml,
range: 69.0-182.0 vs 63.4 mug/ml, range: 3.7-172.0; P < 0.05), but
similar amounts of tryptase and LTC4. This study demonstrated that DL
inhibits activation of both eosinophils and mast cells derived from a
site of airway mucosal inflammation.

Descriptors--Author Keywords: antihistamine ; aspirin sensitivity ; desloratadine ; eosinophils ; mast cells ; nasal polyps
Identifiers--KeyWord Plus(R): LEUKOTRIENE RECEPTOR ANTAGONIST; SEASONAL ALLERGIC RHINITIS; CYTOKINE RELEASE; EPITHELIAL-CELLS; HISTAMINE-RELEASE; MEDIATOR RELEASE; HUMAN BASOPHILS; IN-VITRO; LORATADINE; DESCARBOXYETHOXYLORATADINE

Cited References:

ABDELAZIZ MM, 1998, V101, P410, J ALLERGY CLIN IMMUN
BAROODY FM, 2000, V55, P17, ALLERGY S64
BERTHON B, 1994, V47, P789, BIOCHEM PHARMACOL
BOUSQUET J, 2003, V58, P733, ALLERGY
CAMPBELL A, 1996, V52, P15, DRUGS S1
CARAYOL N, 2002, V57, P1067, ALLERGY
CIPRANDI G, 2003, V112, PS78, J ALLERGY CLIN IM S4
CRAMPIETTE L, 1996, V51, P346, ALLERGY
GEHA RS, 2001, V107, P751, J ALLERGY CLIN IMMUN
GENOVESE A, 1997, V27, P559, CLIN EXP ALLERGY
KLEINETEBBE J, 1994, V93, P494, J ALLERGY CLIN IMMUN
KOWALSKI ML, 2000, V55, P84, THORAX
KOWALSKI ML, 2002, V57, P493, ALLERGY
KUSTERS S, 2002, V52, P97, ARZNEIMITTEL-FORSCH
LEBEL B, 1997, V99, PS444, J ALLERGY CLIN IMMUN
LEBEL B, 1998, V116, P284, INT ARCH ALLERGY IMM
LETARI O, 1994, V266, P219, EUR J PHARM-MOLEC PH
LIPPERT U, 1995, V4, P272, EXP DERMATOL
MASTALERZ L, 2002, V32, P949, EUR J CLIN INVEST
MOLET S, 1997, V27, P1167, CLIN EXP ALLERGY
PAPI A, 2001, V108, P221, J ALLERGY CLIN IMMUN
RAGAB S, 2001, V31, P1385, CLIN EXP ALLERGY
SCHROEDER JT, 2001, V31, P1369, CLIN EXP ALLERGY
SIMONS FER, 2002, V110, P777, J ALLERGY CLIN IMMUN
STOOP AE, 1993, V91, P616, J ALLERGY CLIN IMMUN
SZCZEKLIK A, 1999, V104, P5, J ALLERGY CLIN IMMUN
VIGNOLA AM, 1995, V50, P200, ALLERGY

3/5/6 (Item 2 from file: 34)

DIALOG(R) File 34:SciSearch(R) Cited Ref Sci
(c) 2006 Inst for Sci Info. All rts. reserv.

05347890 Genuine Article#: VR622 Number of References: 51
Title: INFLUENCE OF FOOD ON THE ORAL BIOAVAILABILITY OF LORATADINE AND PSEUDOEPHEDRINE FROM EXTENDED-RELEASE TABLETS IN HEALTHY-VOLUNTEERS
Author(s): NOMEIR AA; MOJAVERIAN P; KOSOGLOU T; AFFRIME MB; NEZAMIS J; RADWANSKI E; LIN CC; CAYEN MN
Corporate Source: SCHERING PLOUGH CORP,RES INST,DEPT DRUG METAB &PHARMACOKINET,MAIL STOP 2880/KENILWORTH//NJ/07033; SCHERING PLOUGH CORP,RES INST,DEPT CLIN PHARMACOL/KENILWORTH//NJ/07033; SCHERING PLOUGH CORP,RES INST,DEPT BIOSTAT/KENILWORTH//NJ/07033
Journal: JOURNAL OF CLINICAL PHARMACOLOGY, 1996, V36, N10 (OCT), P923-930
ISSN: 0091-2700
Language: ENGLISH Document Type: ARTICLE
Geographic Location: USA
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences; CC CLIN-- Current Contents, Clinical Medicine
Journal Subject Category: PHARMACOLOGY & PHARMACY
Abstract: The effect of a high-fat breakfast on the bioavailability of the components of an extended-release tablet containing 10 mg loratadine in the immediate-release coating and 240 mg pseudoephedrine sulfate in the extended-release core was studied in 24 healthy male volunteers in a single-dose, two-way crossover study. The drug was administered after a 10-hour overnight fast or within 5 minutes of consuming a standardized high-fat breakfast. Serial blood samples were collected over a 48-hour period, and plasma was analyzed

for loratadine and its active metabolite

descarboethoxyloratadine (DCL), and pseudoephedrine. For pseudoephedrine, maximum concentration (C_{max}) and area under the concentration-time curve extrapolated to infinity (AUC_{0-(infinity)}) were similar after both treatments, indicating no relevant food effect on the bioavailability of pseudoephedrine. Also, the absorption profiles of pseudoephedrine (from Wagner-Nelson analysis) were similar for the fed and fasted treatments, indicating no apparent differences in absorption. Plasma concentration-time profiles and values for C_{max} and AUC_{0-(infinity)} of DCL were similar for the two treatments, indicating no relevant food effect on the pharmacokinetics of DCL. In contrast, for ***loratadine***, administration with food resulted in a significantly increased mean C_{max} (53%) and AUC from time zero to the final quantifiable sample (AUC_{tf}) (76%). However, the resultant C_{max} and AUC of loratadine under fed conditions were well below those previously obtained at steady-state after multiple-dose administration of loratadine (40 mg/day) that were shown to be safe and well-tolerated in several clinical studies. The effect of food on the bioavailability and pharmacokinetic profiles of the components of a combination loratadine/pseudoephedrine extended-release tablet is not likely to be clinically significant.

Identifiers--KeyWords Plus: SEASONAL ALLERGIC RHINITIS; NON-SEDATING ANTIHISTAMINE; SENSITIVE ASSAY; HUMAN PLASMA; EFFICACY; SAFETY; PHARMACOKINETICS; TRIPROLIDINE; COMBINATION; TERFENADINE

Research Fronts: 94-0954 001 (NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ISOZYME-SELECTIVE PHOSPHODIESTERASE INHIBITORS; TREATMENT OF ACID-RELATED DISEASE)

94-1191 001 (TERFENADINE METABOLISM; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; DEPRESSION MANAGEMENT; PHARMACODYNAMICS OF PAROXETINE; H-1-RECEPTOR ANTAGONISTS)

94-1981 001 (ABSOLUTE BIOAVAILABILITY; DRUG DISSOLUTION; IN-VITRO IN-VIVO CORRELATIONS; ONE-COMPARTMENT BODY MODEL; SOLID DISPERSIONS; FIRST-ORDER ELIMINATION)

94-5128 001 (INTRAMUSCULAR DICLOFENAC SODIUM FOR POSTOPERATIVE ANALGESIA; LAPAROSCOPIC STERILIZATION; REDUCTION OF PAIN)

Cited References:

SHER PLOUGH RES I, 1985, C8407201 SCHER PLOUGH
WISC AN RES SERV, 1991, 00102 P WARS
BAASKE DM, 1979, V68, P1472, J PHARM SCI
BARNETT A, 1984, V14, P590, AGENTS ACTIONS
BEDARD PM, 1985, V55, P233, ANN ALLERGY
BENEZRA SA, 1979, P489, ANAL PROFILES DRUG S
BRATER DC, 1980, V28, P690, CLIN PHARMACOL THER
BRUTTMANN G, 1987, V15, P63, J INT MED RES
BYE C, 1975, V8, P47, EUR J CL PH
CHAO ST, 1991, V80, P432, J PHARM SCI
CLISSOLD SP, 1989, V37, P42, DRUGS
CONNELL JT, 1979, V42, P278, ANN ALLERGY
CONNELL JT, 1982, V10, P341, J INT MED RES
DELBEKE FT, 1991, V12, P37, BIOPHARM DRUG DISPOS
DELCARPIO J, 1989, V84, P741, J ALLERGY CLIN IMMUN
DIAMOND L, 1981, V47, P87, ANN ALLERGY
DICKERSON J, 1978, V14, P253, EUR J CLIN PHARMACOL
DOCKHORN RJ, 1987, V58, P407, ANN ALLERGY
EMPEY DW, 1975, V34, P41, ANN ALLERGY
FALLIERS CJ, 1980, V45, P75, ANN ALLERGY
FRIEDMAN HM, 1987, V1, P95, AM J RHINOL
GAMMANS RE, 1986, V80, P41, AM J MED
GIBALDI M, 1982, PHARMACOKINETICS
GRAVES DA, 1988, V9, P267, BIOPHARM DRUG DISPOS
HARIA M, 1994, V48, P617, DRUGS
HEBBARD GS, 1995, V28, P41, CLIN PHARMACOKINET
HEBERT J, 1988, V2, P71, AM J RHINOL
HILBERT J, 1987, V27, P694, J CLIN PHARMACOL

HWANG SS, 1995, V35, P259, J CLIN PHARMACOL
JOHNSON DA, 1993, V13, S110, PHARMACOTHERAPY
JOHNSON R, 1994, V657, P125, J CHROMATOGR B
KAMINSZCZIK I, 1986, 13 C EUR AC ALL CLIN
KANFER I, 1993, V13, S116, PHARMACOTHERAPY
KATCHEN B, 1985, V55, P393, ANN ALLERGY
KREUTNER W, 1987, V42, P57, ALLERGY
KUNTZMAN RG, 1971, V12, P62, CLIN PHARMACOL THER
LAI CM, 1979, V68, P1243, J PHARM SCI
LO LY, 1981, V222, P297, J CHROMATOGR
LUCAROTTI RL, 1972, V61, P903, J PHARM SCI
MELANDER A, 1977, V22, P104, CLIN PHARM
MELANDER A, 1977, V30, P108, CLIN PHARMACOL THER
PREVOST M, 1994, V16, P50, CLIN THER
RADWANSKI E, 1987, V27, P530, J CLIN PHARMACOL
SCHUIRMANN DJ, 1987, V15, P657, J PHARMACOKINET BIOP
THOMSON WAR, 1967, V198, P713, PRACTITIONER
VANCAUWENBERGE PB, 1992, V4, P283, DRUG INVEST
WAGNER JG, 1964, V53, P1392, J PHARM SCI
WECKER MT, 1987, V76, P29, J PHARM SCI
WELLING PG, 1977, V5, P291, J PHARMACOKINET BIOP
WELLING PG, 1986, PHARMACOKINETICS PRO
WILLIAMS BO, 1984, V3, P638, CLIN PHARMACY

3/5/7 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

12099752 PMID: 15992014

Therapeutic advantages of third generation antihistamines.

Handley D A; Magnetti A; Higgins A J

Sepracor, Inc., 111 Locke Drive, Marlborough, MA 01752, USA.

Expert opinion on investigational drugs (England) Jul 1998, 7 (7)

p1045-54, ISSN 1744-7658--Electronic Journal Code: 9434197

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: PubMed not MEDLINE

Subfile: Toxbib

A third generation of antihistamines is emerging for the treatment of allergic ***rhinitis*** and chronic urticaria. First generation antihistamines are among the most widely used drugs in the world, and provide symptomatic relief from allergies and the common cold to millions of patients, mainly in OTC combination preparations. Their full potential is limited by the sedation caused by their effects on histamine receptors in the brain. Second generation antihistamines (terfenadine, astemizole, loratadine and cetirizine), which block peripheral H1 receptors without penetrating the blood-brain barrier, were developed and introduced from 1981 onwards to provide comparable therapeutic benefit without the CNS side-effects. Although largely successful in this goal, terfenadine and astemizole were found to cause potentially serious arrhythmias when plasma concentrations became elevated subsequent to impaired metabolism. It was established that the cardiac toxicity was mainly due to the parent drugs. As active metabolites could account for most of the clinical benefit, the goal for the third generation of antihistamines became to develop therapeutically active metabolites that were devoid of cardiac toxicity. The first of these drugs, fexofenadine (the active metabolite of terfenadine), was approved in July 1996, after an unusually rapid development programme. Its introduction set a new standard of safety that led the FDA to request the withdrawal of terfenadine in 1997 on the grounds that a safer version of an equivalent drug was now available. Norastemizole and descarboethoxy loratadine, the metabolites of astemizole

and ***loratadine***, respectively, are also in clinical development. These offer comparable or superior clinical benefits.

Record Date Created: 20050704

Record Date Completed: 20050721

3/5/8 (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

133266736 CA: 133(19)266736c PATENT
Preparation of fluorinated descarboethoxyloratadine for treatment of
allergic and related disorders.
INVENTOR(AUTHOR): Piwinski, John J.; Schumacher, Doris P.; Aronov, Evgeny
; Khusid, Anatoliy
LOCATION: USA
ASSIGNEE: Schering Corporation
PATENT: PCT International ; WO 200057880 A1 DATE: 20001005
APPLICATION: WO 2000US8080 (20000327) *US 281115 (19990329)
PAGES: 19 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-031/445A; A61P-011/02B; A61P-011/06B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;
CH; CN; CR; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN;
IS; JP; KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; NO; NZ;
PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; US; UZ; VN; YU;
ZA; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE;
SN; TD; TG
SECTION:
CA227016 Heterocyclic Compounds (One Hetero Atom)
CA201XXX Pharmacology
IDENTIFIERS: fluorodescarboethoxyloratadine prepn allergy inhibitor,
loratadine fluoro descarboethoxy prepn allergic rhinitis treatment,
antihistamine fluorodescarboethoxyloratadine prepn
DESCRIPTORS:
Nose...
allergic rhinitis, treatment; prepn. of fluorinated
descarboethoxyloratadine for treatment of allergic and related
disorders
Allergy inhibitors... Antihistamines...
prepn. of fluorinated descarboethoxyloratadine for treatment of
allergic and related disorders
CAS REGISTRY NUMBERS:
125743-80-8 298220-99-2P prepn. of fluorinated descarboethoxyloratadine
for treatment of allergic and related disorders

3/5/9 (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

129180143 CA: 129(14)180143n PATENT
Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions
of descarboethoxyloratadine
INVENTOR(AUTHOR): Redmon, Martin P.; Butler, Hal T.; Wald, Stephen A.;
Rubin, Paul D.
LOCATION: USA
ASSIGNEE: Sepracor, Inc.
PATENT: PCT International ; WO 9834614 A1 DATE: 19980813
APPLICATION: WO 98US2328 (19980206) *US 37325 (19970207) *US 45184
(19970430) *US 53050 (19970721)
PAGES: 34 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-031/445A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

SECTION:

CA263006 Pharmaceuticals

IDENTIFIERS: lactose free nonhygroscopic descarboethoxyloratadine, descarboethoxy loratadine pharmaceutical

DESCRIPTORS:

Blood vessel...

disorders; lactose-free, non-hygroscopic and anhyd. pharmaceutical compns. of descarboethoxyloratadine

Allergic rhinitis... Analgesics... Capsules(drug delivery systems)...

Coatings... Decongestants... Dermatitis... Diabetic retinopathy...

Tablets(drug delivery systems)...

lactose-free, non-hygroscopic and anhyd. pharmaceutical compns. of descarboethoxyloratadine

CAS REGISTRY NUMBERS:

51-45-6 biological studies, -induced disorders; lactose-free, non-hygroscopic and anhyd. pharmaceutical compns. of descarboethoxyloratadine

9004-32-4 9004-62-0 9004-64-2 9004-65-3 9004-67-5 9032-42-2
37353-59-6 film-former; lactose-free, non-hygroscopic and anhyd. pharmaceutical compns. of descarboethoxyloratadine

50-78-2 103-90-2 15687-27-1 22071-15-4 22204-53-1 100643-71-8
lactose-free, non-hygroscopic and anhyd. pharmaceutical compns. of descarboethoxyloratadine

3/5/10 (Item 3 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

125177434 CA: 125(14)177434V PATENT

Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

INVENTOR(AUTHOR): Aberg, A. K. Gunnar; McCullough, John R.; Smith, Emil

R.

LOCATION: USA

ASSIGNEE: Sepracor, Inc.

PATENT: PCT International ; WO 9620708 A1 DATE: 960711

APPLICATION: WO 95US15995 (951211) *US 366651 (941230)

PAGES: 35 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-031/44A

DESIGNATED COUNTRIES: AL; AM; AU; BB; BG; BR; BY; CA; CN; CZ; EE; FI; GE; HU; IS; JP; KG; KP; KR; LK; LR; LS; LT; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; RO; RU; SG; SI; SK; TJ; TM; TT; UA; UZ; VN DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

SECTION:

CA263006 Pharmaceuticals

CA201XXX Pharmacology

IDENTIFIERS: allergic rhinitis treatment descarboethoxy loratadine

DESCRIPTORS:

Neoplasm...

avoidance of promotion of; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Heart, disease, arrhythmia...

avoidance of; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Electric activity...

cardiac rectifying potassium current; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Receptors, histaminic H1...

descarboethoxyloratadine binding to; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Analgesics... Antihistaminics... Antipyretics... Cottonseed oil...

Eye, disease, diabetic retinopathy... Lecithins... Nose, disease, rhinitis, allergic... Olive oil... Pharmaceutical dosage forms, capsules...

Pharmaceutical dosage forms, capsules, soft... Pharmaceutical dosage forms, tablets... Soybean oil...

methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Urticaria...

treatment of; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

CAS REGISTRY NUMBERS:

7631-86-9 biological studies, colloidal; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

9035-51-2 biological studies, inhibition of, avoidance of; methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

9004-34-6 9005-25-8 biological studies, methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine

63-42-3 557-04-0 79794-75-5 100643-71-8P methods and compns. for treating allergic rhinitis and other disorders using descarboethoxyloratadine